Latest Executive Appointments News

King River Resources has appointed seasoned geologist and executive Graham Gadsby as Managing Director, aiming to leverage his proven track record in gold exploration and operational turnarounds to drive the company’s future growth.

Iress Limited has appointed Andrew Russell as its new Group CEO, marking a strategic leadership shift following a major company transformation. Russell’s extensive fintech experience positions him to lead Iress into a product and client-focused future.

Nanoveu Limited’s transformative half-year report highlights its EMASS acquisition, executive hires, and technology advances amid a $3 million loss and new US OTCQB listing.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Elixinol Wellness Limited reported a 12.8% increase in revenue to $7.64 million for the half-year ended June 2025, yet its net loss widened by 12.2% to $3.09 million, reflecting higher marketing and restructuring expenses following recent acquisitions.

Aerometrex reported a mixed FY25 with strong MetroMap subscription growth boosting EBITDA despite a decline in LiDAR revenue. The company also appointed Robert Veitch as CEO, signaling a strategic focus on SaaS expansion and diversified geospatial solutions.

DorsaVi Limited reported a 13.9% revenue decline and a 21.7% rise in net loss for FY25, while securing over $3 million in capital to fuel new technology ventures.

Structural Monitoring Systems plc has reported its first profit after tax, driven by strong avionics sales and a successful $8.7 million capital raise. The company’s strategic shift towards proprietary products and key certifications underpin a positive outlook.

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.

Bapcor Limited reported a decline in FY25 pro-forma net profit after tax by 8.4%, alongside a successful $170 million debt refinancing extending maturities to 2029-2031. The company declared a fully franked final dividend and announced significant board and executive changes.

Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.

Aeris Resources Limited reported a robust financial turnaround for FY25, posting a $45.2 million profit and a 68% rise in adjusted EBITDA, underpinned by steady copper and gold production and strategic refinancing.